Treatment of acute leukemia with 5-azacytidine (NSC-102816).
D000293:Adolescent; D000328:Adult; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets; D001803:Blood Transfusion; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D001374:Azacitidine